Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD47-CD138 bispecific antibody
- Development stage
- Preclinical
- Lead developer
- Medical College of Wisconsin
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The CD47-CD138 bispecific antibody is a preclinical therapeutic candidate designed for the treatment of multiple myeloma (MM). Developed by researchers at the Medical College of Wisconsin, this bispecific antibody (BsAb) utilizes a single-chain variable fragment (scFv) format, linking an anti-CD47 scFv with an anti-CD138 scFv via a human serum albumin (HSA) linker. The drug's mechanism of action involves dual-targeting: it binds to CD138 (Syndecan-1), which is highly and specifically expressed on multiple myeloma cells, and simultaneously blocks CD47, a "do not eat me" signal that inhibits phagocytosis by interacting with SIRP-alpha on macrophages. By preferentially binding to MM cells, the antibody aims to enhance tumor-specific phagocytosis while reducing the "sink effect" and off-target toxicities (such as anemia or T-cell depletion) typically associated with systemic CD47 blockade.
- Other names
- CD47-CD138 BsAbCD-47-CD138 BsAbCD 47-CD138 BsAb
02
Targets
CD47 (Cluster of Differentiation 47)SDC1 (Syndecan-1)
Beyond the preview
Go deeper on CD47-CD138 bispecific antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD47-CD138 bispecific antibody.